Jason M. Redman, M.D.

Jason M. Redman, M.D.

  • Center for Cancer Research
  • National Cancer Institute
Center for Immuno-Oncology


Dr. Redman is a physician treating cancer patients with combinations of immunotherapy, chemotherapy and other therapies. He works on clinical trials for patients with prostate cancer, colon cancer, head and neck cancer, and other solid tumors.

The immune system is a complex network traditionally known for fighting infections. However, it can also fight cancer. Cancer immunotherapy refers to drug treatments designed to help the immune system recognize and fight cancer. In some cases, these treatments can lead to significant and long-lasting decreases in cancer burden. Dr. Redman is a member of the Center for Immuno-Oncology (CIO). He works closely with scientists who study the effects of immunotherapy on cancer in the laboratory. This research guides selection of drug combinations for use in clinical trials.

Areas of Expertise

1) combination immunotherapy for cancer 2) therapeutic cancer vaccines 3) colon cancer 4) prostate cancer 5) immune checkpoint inhibitors

Information for Patients

Learn more about our clinical trials and the highly specialized care teams that lead them.


Selected Key Publications

Spotlight on atezolizumab and its potential as an oncology agent

Redman JM, Madan RA.
Expert Review of Anticancer Therapy. 18(8): 719-722, 2018. [ Journal Article ]

Combining immunotherapies for the treatment of prostate cancer

Redman JM, Gulley JL, Madan RA
Urologic Oncology. 35(12): 694-700, 2017. [ Journal Article ]

Advances in Immunotherapy for Melanoma

Redman JM, Gibney, GT, Atkins MB.
BioMed Central Medicine. 14: 20, 2016. [ Journal Article ]

Mechanisms of action of therapeutic antibodies for cancer

Redman JM, Hill EM, AlDeghaither D, Weiner LM.
Molecular Immunology. 67(2 Pt A): 28-45, 2015. [ Journal Article ]